Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, ... Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Mostrar más
The DJS Law Group announces that it is investigating claims on behalf of investors of Neumora Therapeutics, Inc. (“Neumora” or “the Company”) (NASDAQ: NMRA) for violations of the securities laws...
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an...
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025 Ongoing clinical studies evaluating...
WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven...
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven...
| Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.2709 | -11.5276595745 | 2.35 | 2.44 | 2.05 | 3557598 | 2.26688921 | CS |
| 4 | -8.0909 | -79.5565388397 | 10.17 | 11.57 | 1.83 | 6966078 | 2.69187101 | CS |
| 12 | -10.9809 | -84.0803981623 | 13.06 | 14.09 | 1.83 | 2785681 | 4.79434308 | CS |
| 26 | -9.6909 | -82.3355989805 | 11.77 | 17.1874 | 1.83 | 1698894 | 7.08385294 | CS |
| 52 | -11.7909 | -85.0100937275 | 13.87 | 21 | 1.83 | 1141083 | 8.29790458 | CS |
| 156 | -14.4209 | -87.3993939394 | 16.5 | 21 | 1.83 | 943283 | 8.73064054 | CS |
| 260 | -14.4209 | -87.3993939394 | 16.5 | 21 | 1.83 | 943283 | 8.73064054 | CS |
glenn1919
6 días hace
glenn1919
2 semanas hace
glenn1919
3 semanas hace
glenn1919
3 semanas hace
TheFinalCD
3 semanas hace
Monksdream
3 meses hace
Monksdream
7 meses hace
Monksdream
9 meses hace
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones
Hot Features
Premium
